Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major histocompatibility complex class II (MHC II) proteins are membrane-bound glycoproteins essential for the adaptive immune response. They present peptide antigens derived from extracellular proteins to CD4+ T lymphocytes, thereby initiating and regulating immune responses against pathogens and foreign antigens. MHC II molecules are heterodimers composed of an α (alpha) chain and a β (beta) chain. They are constitutively expressed on professional antigen-presenting cells (APCs): dendritic cells, macrophages/monocytes, B cells, and also found on thymic epithelial cells. Expression can be induced on other cell types by interferon gamma (IFNγ). MHC class II molecules play a central role in orchestrating adaptive immunity through their unique ability to sample extracellular environments and present processed antigens specifically recognized by helper T lymphocytes—a process fundamental both during infection control and vaccine-induced protection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major Histocompatibility Complex Class II Protein (MHC II).